BeOne Medicines Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ONC research report →
Companybeonemedicines.com
BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.
- CEO
- John V. Oyler
- IPO
- 2016
- Employees
- 11,000
- HQ
- US
Price Chart
Valuation
- Market Cap
- $32.99B
- P/E
- 100.38
- P/S
- 6.50
- P/B
- 10.83
- EV/EBITDA
- 43.20
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 87.17%
- Op Margin
- 11.96%
- Net Margin
- 8.93%
- ROE
- 12.10%
- ROIC
- 7.82%
Growth & Income
- Revenue
- $5.34B · 40.23%
- Net Income
- $286.93M · 144.50%
- EPS
- $33.80 · 652.29%
- Op Income
- $447.14M
- FCF YoY
- 240.61%
Performance & Tape
- 52W High
- $385.22
- 52W Low
- $234.80
- 50D MA
- $299.89
- 200D MA
- $321.10
- Beta
- 0.50
- Avg Volume
- 246.19K
Get TickerSpark's AI analysis on ONC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 27, 24 | Sharp Shalini | other | 0 |
| May 13, 26 | Lee Chan Henry | other | 1,274 |
| May 13, 26 | Lee Chan Henry | other | 1,729 |
| May 13, 26 | Lee Chan Henry | other | 1,313 |
| May 13, 26 | Lee Chan Henry | other | 98 |
| May 13, 26 | Lee Chan Henry | other | 133 |
| May 13, 26 | Lee Chan Henry | other | 101 |
| May 13, 26 | Lee Chan Henry | sell | 332 |
| Apr 8, 26 | Lee Chan Henry | other | 1,274 |
| Apr 8, 26 | Lee Chan Henry | other | 1,729 |
Our ONC Coverage
We haven't published any research on ONC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ONC Report →